Inhibrx Biosciences Inc. (INBX) Stock Analysis & Investment Frameworks
Inhibrx Biosciences Inc. (INBX) stock analysis on Invetso. Review Inhibrx Biosciences Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Inhibrx Biosciences Inc. Company Overview
- Exchange: NASDAQ
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Inhibrx Biosciences Inc. Key Financial Metrics
- Market Cap: $1.28B
- Revenue: $1.30M
- ROE: 1893.60%
- ROIC: -99.35%
- Dividend Yield: N/A
About Inhibrx Biosciences Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.